Valbiotis SA (EPA:ALVAL)

Market Cap	18.33M
Revenue (ttm)	176.00K
Net Income (ttm)	-10.03M
Shares Out	15.88M
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,502
Average Volume	65,908
Open	1.140
Previous Close	1.154
Day's Range	1.130 - 1.158
52-Week Range	0.941 - 4.000
Beta	-0.30
RSI	58.85
Earnings Date	Jun 27, 2025

About Valbiotis

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laborato...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 44
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALVAL

Financial Performance

In 2024, Valbiotis's revenue was 176,000, a decrease of -96.28% compared to the previous year's 4.73 million. Losses were -10.03 million, 36.1% more than in 2023.